Current Reviews in Clinical and Experimental Pharmacology最新文献

Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.

The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorialpolicies-main.php.

Bentham science disclaimer: It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneouslysubmitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewheremust be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submittingthe article for publication the authors agree that the publishers have the legal right to take appropriate action against theauthors, if plagiarism or fabricated information is discovered. By submitting a manuscript, the authors agree that the copyrightof their article is transferred to the publishers if and when the article is accepted for publication.

Background: Successful integration of in vitro into in vivo data on Drug-Drug Interaction (DDI) is dependent on the inhibitory concentration used. Obtaining plasma concentration of a drug is only readily available for a small number of drugs in clinical practice. We propose the use of a therapeutic range as a substitute for inhibitory concentration.

Objective: Because of this, we aimed to construct a linear-regression model based on the areaunder- curve of the victim drugs and the therapeutic range for a set of known inhibitors of the CYP2D6 of interest.

Methods: Correlation analysis of linear log-log regression of two main variables: The Area-Under- Curve ratio (AUCr) of the victim drugs and the therapeutic range-to-inhibition constant ratio, with data obtained from literature.

Results: Data were fitted to linear log-log regression, between the average of AUCr values and mean value of therapeutic range-to-inhibition constant ratio (TR_m-to-K_i), of the inhibitory drugs.

Conclusion: According to our results, knowledge of the inhibition constant and therapeutic range (or its plasma levels if disponible) of the inhibitor would be sufficient to determine the intensity and clinical relevance of a CYP2D6-mediated DDI.

Background: Coronary artery disease is a major cause of morbidity and mortality worldwide. A major health concern in the developing countries is opioid addiction, which has controversial cardiovascular side effects. We aimed to investigate whether Myocardial Infarction (MI) and its risk factors are associated with morphine dependency in the Iranian population.

Methods: Electronic databases, including PubMed, Medline, Scopus, SID, Element, and Magiran were searched to find published articles including the keywords morphine, coronary artery disease, hypertension, hyperlipidemia, and diabetes mellitus.

Results: Twelve studies involving 25,800 people were included in this systematic review and metaanalysis. Morphine dependency was significantly associated with MI with an adjusted odds ratio (AOR) of 2.28 (95%CI=1.26-4.11). It neither has significant associations with hypertension (AOR=0.952; 95%CI=0.696-1.301) nor diabetes (AOR=0.895; 95%CI=0.644-1.246). Morphine dependency also had no significant association with hyperlipidemia with a Crude Odds Ratio (COR) of 0.906 (95%CI=0.786-1.045).

Conclusion: Morphine dependency was significantly related to MI, but its risk factors were not significantly associated with morphine dependency. The increasing prevalence of opioid abuse in developing countries may be a reason for the growing incidence of MI in younger ages and individuals with no risk factors. Besides, physicians should consider the presence of impurities in morphine-based opioids and their possible effects on health.